Disclosure Of Interests In Other Entities [Text Block]

Egetis Therapeutics - Filing #690710

Concept	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	As at 2020-12-31
Disclosure of interests in other entities [text block]	—	—	—	NOT 19	—	—	—	—	—	—	—	—	—
Disclosure of interests in subsidiaries [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of subsidiaries [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of subsidiaries [abstract]
Disclosure of subsidiaries [line items]
Current assets	1,474,000,000 SEK	—	—	—	—	—	1,529,000,000 SEK	—	—	—	—	—	—
Non-current assets	4,137,000,000 SEK	—	—	—	—	—	4,164,000,000 SEK	—	—	—	—	—	—
Current liabilities	494,000,000 SEK	—	—	—	—	—	392,000,000 SEK	—	—	—	—	—	—
Non-current liabilities	55,000,000 SEK	—	—	—	—	—	31,000,000 SEK	—	—	—	—	—	—
Revenue	—	—	—	226,000,000 SEK	—	—	—	—	—	—	382,000,000 SEK	—	—
Profit (loss)	—	—	—	1,938,000,000 SEK	—	—	—	—	—	—	1,045,000,000 SEK	—	—
Comprehensive income	—	– SEK	– SEK	1,938,000,000 SEK	1,938,000,000 SEK	– SEK	—	– SEK	– SEK	– SEK	1,045,000,000 SEK	1,045,000,000 SEK	—
Disclosure of interests in associates [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of associates [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of associates [abstract]
Disclosure of associates [line items]
Other comprehensive income	—	—	—	0 SEK	—	—	—	—	—	—	- SEK	—	—
Disclosure of interests in joint arrangements [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of joint ventures [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of joint ventures [abstract]
Disclosure of joint ventures [line items]
Cash and cash equivalents	1,277,000,000 SEK	—	—	—	—	—	1,440,000,000 SEK	—	—	—	—	—	2,879,000,000 SEK
Tax expense (income)	—	—	—	- SEK	—	—	—	—	—	—	- SEK	—	—